• The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • ALXN1210-MG-306

    Enrollment Information

    Call (602) 406-6606 or E-Mail [email protected]

    Gregory W. Fulton Neuromuscular Center

    Learn More

    The purpose of this study is to evaluate the efficacy and safety of Ravulizumab, which is being developed to treat generalized myasthenia gravis by blocking abnormal complement activity, which is the part of the immune system that fights against infections. Ravulizumab is administered via intravenous infusions over a 26-week treatment period (i.e. two loading doses administered approximately once 2 weeks apart, followed by 2 maintenance doses administered approximately 8 weeks apart).

    In addition to the study drug infusions, participants will complete study visits to assess clinical outcomes on a weekly basis for the first month, then bi-weekly for about two months, and finally monthly for the last three months.

    Overall, participants will be in the research study for approximately 26 weeks, with the option to continue for up to 2 years in an open label extension study.

    Principal Investigator: Suraj Muley, MD

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.